A letter went out alerting doctors about cases of liver damage among patients who took the cancer med in a post-approval study. One patient died from rapidly progressing liver failure and another died from a liver complication called hepatorenal syndrome, according to the letter sent by Genentech and OSI Pharmaceuticals.
Read article at pharmalot.com
No comments:
Post a Comment